scholarly journals The Effect of Glycated Hemoglobin on the Prognosis of Diabetic Patients: A Cross-Sectional Observational Study

2019 ◽  
Vol 9 (1) ◽  
pp. 5-11
Author(s):  
Abdullah N. Alkattan ◽  
Ahmed S. Alkhalifah ◽  
Eman A. Alsalameen
Keyword(s):  
Saudi Arabia ◽  
Observational Study ◽  
Advanced Glycation End Products ◽  
Hemoglobin A1c ◽  
Glycated Hemoglobin ◽  
Diabetic Patients ◽  
Advanced Glycation ◽  
Cross Sectional ◽  
Glycation End Products ◽  
End Products

Objectives: Diabetes mellitus is a chronic metabolic disorder characterized by elevation of blood glucose and a high percentage of glycated hemoglobin A1c. Elevated hemoglobin A1c percentage of more than 7% will result in high production of advanced glycation end-products. Th e elevated level of advanced glycation end-products in diabetic patients means a high risk for diabetic complications. Th e primary endpoint was to evaluate the hemoglobin A1c levels among diabetic patients and its effect on the prognosis of this metabolic disease in all regions inside Saudi Arabia. Methods: Th is was a cross-sectional observational study conducted between March and August 2018. Th e study was done by using a questionnaire containing nine questions which planned to involve at least 390 diabetic patients. Results: Six hundred and ninety-four diabetic patients from Saudi Arabia had answered the nine-question questionnaire about hemoglobin A1c percentage and prognosis of diabetes. Th e mean age of these patients is 43.4 years old and most of those patients (75.5%) were visiting governmental hospitals. Th e number of diabetic patients having hemoglobin A1c less than 7% are 259 patients with hemoglobin A1c mean 6.66% + 3.33%, however, there are 435 patients having hemoglobin A1c more than 7% with mean equals 7.75% + 1.2%, the difference between them is statistically significant (P value < 0.0001). Conclusion: Th e glycated hemoglobin of diabetic patients in all regions of Saudi Arabia was significantly elevated and uncontrolled based on most diabetic guidelines and significantly affects the prognosis by causing diabetic complications especially cardiovascular diseases.

scholarly journals De Novo Hepatocellular Carcinoma in Hepatitis C-Related Cirrhosis: Are Advanced Glycation End Products a Key Driver?

2021 ◽  
Vol 11 ◽  
Author(s):  
Ahmed Abdel-Razik ◽  
Walaa Shabana ◽  
Ahmed Mohamed El Nakib ◽  
Mostafa Abdelsalam ◽  
Ahmed Abdelwahab ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Regression Analysis ◽  
Hepatitis C ◽  
Advanced Glycation End Products ◽  
Cox Regression ◽  
Diabetic Patients ◽  
Advanced Glycation ◽  
Cox Regression Analysis ◽  
Glycation End Products ◽  
End Products

Background and PurposeThe advanced glycation end products (AGEs) have been implicated in different diseases’ pathogenesis, but their role in hepatocellular carcinoma (HCC) is still a matter of debate. This study aims to investigate the association of AGEs with HCC development in patients with hepatitis C-related cirrhosis.MethodsOnly 153 of the 181 non-diabetic patients with cirrhosis were consecutively involved in this pilot cohort prospective study, along with 34 healthy control participants. Demographic characteristics, biochemical parameters, clinical data, and AGEs levels in all subjects at the starting point and every year after that for two years were assessed. Multivariable Cox regression analysis was used to settle variables that could predict HCC development within this period.ResultsHCC developed in 13 (8.5%) patients. Univariate Cox regression analysis reported that body mass index (P=0.013), homeostatic model assessment-insulin resistance (P=0.006), alpha-fetoprotein (P &lt;0.001), and AGEs levels (P &lt;0.001) were related to HCC development. After adjusting multiple confounders, the multivariable Cox regression model has revealed that AFP and AGEs were the powerful parameters related to the HCC occurrence (all P&lt;0.05). AGEs at a cutoff value of more than 79.6 ng/ml had 100% sensitivity, 96.4% specificity, and 0.999 area under the curve (all P&lt;0.001), using the receiver operating characteristic curve, for prediction of HCC development.ConclusionThis work suggests that AGEs are associated with an increased incidence of HCC, particularly in cirrhosis, which is encouraging in decreasing the risk of HCC in these patients.

Advanced glycation end-products associate with podocytopathy in type II diabetic patients

2021 ◽  
Author(s):  
Rajkishor Nishad ◽  
Tahaseen V Syed ◽  
Manga Motrapu ◽  
Rajesh Kavvuri ◽  
Kiranmayi Kodali ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Kidney Function ◽  
Advanced Glycation End Products ◽  
Diabetic Patients ◽  
Type Ii ◽  
Advanced Glycation ◽  
Mesenchymal Transition ◽  
Glycation End Products ◽  
End Products ◽  
Carboxymethyl Lysine

Abstract Background The prevalence of diabetes reaches epidemic proportions, affecting the incidence of diabetic nephropathy (DN) and associated end-stage kidney disease (ESKD). Diabetes is the leading cause of ESKD since 30–40% of diabetic patients develop DN. Albuminuria and eGFR have been considered a surrogate outcome of chronic kidney disease, and the search for a biomarker that predicts progression to diabetic kidney disease is intense.Methods We analyzed the association of serum advanced glycation end-products (AGEs) index (AGI) with impaired kidney function in uncontrolled diabetic patients (type II, n = 130) with albuminuria ranging from (150 to 450 mg/day). The kidney biopsy specimens were also examined for the association of AGEs, particularly carboxymethyl lysine (CML) with kidney function. Further, we also assessed the effect of carboxymethyl lysine on glomerular injury and podocytopathy in experimental animals.Results We observed a strong correlation between AGI and impaired kidney function in miroalbuminuric patients with hyperglycemia. A significant association between CML levels and impaired kidney function was noticed. Administration of CML in mice showed heavy proteinuria and glomerular abnormalities. Reduced podocyte number observed in mice administered with CML could be attributed to the epithelial-mesenchymal transition (EMT) of podocytes. Conclusion Serum AGEs could be independently related to the podocyte injury vis-a-vis the risk of DN progression to ESKD in patients with microalbuminuria. AGEs or CML could be considered a prognostic marker to assess microalbuminuria progression to ESKD in diabetic patients.

scholarly journals Advanced Glycation End Products Levels and Carotid Intima Media Thickness in Patients With Rheumatoid Arthritis

2019 ◽  
Vol 10 (2) ◽  
pp. 58
Author(s):  
Ines KNANI ◽  
Hassan BOUZIDI ◽  
Albert LECUBE ◽  
Jawhar GHARBI ◽  
Mohsen KERKENI
Keyword(s):  
Rheumatoid Arthritis ◽  
Advanced Glycation End Products ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
Cross Sectional Study ◽  
Advanced Glycation ◽  
Cross Sectional ◽  
Media Thickness ◽  
Glycation End Products ◽  
End Products

Introduction: No data regarding the relationship of carotid intima media thickness (IMT) and serum advanced glycation end products (AGEs) levels in patients with rheumatoid arthritis (RA). The aim of this study is to evaluate the association between IMT and serum pentosidine, CML and MGO levels in patients with longstanding RA.Methods: In a cross-sectional study, 80 consecutive RA patients with longstanding disease were included and compared with 30 age and sex-matched healthy controls. IMT was measured using ultrasonography. AGEs such as pentosidine, Ne-carboxymethyllysine (CML) and methylglyoxal (MGO) as an intermediate of glycation, were determined by ELISA.Results: Serum pentosidine, CML and MGO levels were increased in RA patients vs control subjects (P = 0.001; P < 0.001; P < 0.001 respectively). IMT was increased with disease activity of RA (P = 0.004) and was associated with serum pentosidine (r = 0.460, P < 0.001), serum CML (r = 0.549, P < 0.001) and serum MGO (r = 0.658, P < 0.001). Furthermore, in a multiple stepwise regression analysis CML and MGO were independently associated with IMT (b= 0.333, P = 0.007; b = 0.690, P < 0.001, respectively).Conclusion: serum pentosidine, CML and MGO were increased in RA patients and were significantly related to IMT. Serum CML and MGO were independently associated with IMT.

scholarly journals Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Eva O. Melin ◽  
Jonatan Dereke ◽  
Magnus Hillman
Keyword(s):  
Type 1 Diabetes ◽  
Advanced Glycation End Products ◽  
Inflammatory Responses ◽  
Lipid Lowering ◽  
Advanced Glycation ◽  
Cross Sectional ◽  
Lipid Lowering Drugs ◽  
Glycation End Products ◽  
End Products

Abstract Background The receptors for advanced glycation end products (RAGE) are increased in atherosclerotic plaques. Soluble (s)RAGE decreases, whereas the extracellular newly identified receptor for advanced glycation end products (EN-RAGE) increases inflammatory responses mediated by RAGE. The aims were to explore whether sRAGE, EN-RAGE and the EN-RAGE/sRAGE ratio, were associated with the use of lipid-lowering drugs (LLD) and/or antihypertensive drugs (AHD) in patients with type 1 diabetes (T1D). Methods Cross-sectional design. T1D patients were consecutively recruited from one diabetes clinic. Blood samples were collected, supplemented with data from electronic health records. sRAGE and EN-RAGE were analysed by enzyme linked immunosorbent assays. An EN-RAGE/sRAGE ratio was calculated. Adjustments were performed with inflammatory and metabolic variables, s-creatinine, depression, smoking, physical inactivity, medication, and cardiovascular complications. Multiple regression analyses were performed. Results In this study 283 T1D patients (men 56%, 18–59 years) were included. One-hundred and thirty LLD users compared to 153 non-users had lower levels of the EN-RAGE/sRAGE ratio (P = 0.009), and 89 AHD users compared to 194 non-users had lower levels of sRAGE (P = 0.031). The use of LLD (inversely) (B coefficient − 0.158, P = 0.033) and the use of AHD (B coefficient 0.187, P = 0.023) were associated with the EN-RAGE/sRAGE ratio. sRAGE (Lg10) (per unit) (adjusted odds ratio (AOR) = 3.5, 95% CI = 1.4–9.1, P = 0.009), EN-RAGE (Lg10) (per unit) (inversely) (AOR 0.4, 95% CI = 0.2–1.0, P = 0.046), age (P <  0.001), and triglycerides (P <  0.029), were associated with LLD. sRAGE (Lg10) (per unit) (inversely) (AOR = 0.2, 95% CI = 0.1–0.5, P = 0.001), diabetes duration, triglycerides, s-creatinine, and systolic BP (all P values < 0.043), were associated with AHD. Conclusions Higher sRAGE levels and lower EN-RAGE levels were linked to the use of LLD, whereas lower sRAGE levels were linked to the use of AHD. No other variables but the use of LLD and the use of AHD were linked to the EN-RAGE/sRAGE ratio. This may be of major importance as sRAGE is an inhibitor and EN-RAGE is a stimulator of inflammatory processes mediated by RAGE.

scholarly journals Receptor for advanced glycation end-products and ARDS prediction: a multicentre observational study

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Matthieu Jabaudon ◽  
Pauline Berthelin ◽  
Thibaut Pranal ◽  
Laurence Roszyk ◽  
Thomas Godet ◽  
...  
Keyword(s):  
Observational Study ◽  
Advanced Glycation End Products ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Soluble Receptor for Advanced Glycation End Products and Its Correlation with Vascular Damage in Adolescents with Obesity

2019 ◽  
Vol 92 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Reyna Rodríguez-Mortera ◽  
Claudia Luevano-Contreras ◽  
Sergio Solorio-Meza ◽  
Armando Gómez-Ojeda ◽  
Russell Caccavello ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Vascular Damage ◽  
Atherogenic Index ◽  
Stiffness Index ◽  
Model Assessment ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Cross Sectional ◽  
Glycation End Products ◽  
End Products

Objective: The aim of this study was to evaluate soluble receptor for advanced glycation end products (sRAGE) and advanced glycation end products (AGEs) in adolescents with and without obesity (OB) and their correlation with vascular damage. Methods: This is a cross-sectional study with 15–19 years old adolescents: 33 with OB and 33 with normal weight (NW), each group included 17 male and 16 female. Lipid profile, insulin, carboxymethylysine (CML), sRAGE, total AGEs, and dietary AGEs intake (dAGEs) were evaluated. Vascular damage was measured by flow-mediated vasodilation (FMD) and arterial stiffness index (Iβ). Homeostatic model assessment-insulin (HOMA-IR) and atherogenic index (AI) were calculated. Results: The group with OB had higher triglycerides (TG; p < 0.0001), AI (p < 0.001), HOMA-IR (p < 0.0001), dAGEs intake (p < 0.0001), lower CML (p = 0.05), total AGEs (p < 0.01), sRAGE (p < 0.001), and FMD (p < 0.002). In the total group, sRAGE correlated with AI (r = –0.26 p = 0.037); in the NW group, CML correlated with Iβ (r = –0.36; p = 0.037); and in the group of adolescents with OB, sRAGE correlated with FMD (r = –0.37; p = 0.037) and Iβ (r = 0.47; p = 0.006), while CML and total AGEs correlated with AI, p = 0.007 and p < 0.01, respectively). Conclusions: The group of adolescents with OB showed higher cardiometabolic risk as shown by higher TG, AI, HOMA-IR, and lower sRAGE and FMD. sRAGE correlated negatively with FMD and positively with Iβ, so it could be suggested as a biochemical marker of impaired endothelial function.

scholarly journals Detection of Noncarboxymethyllysine and Carboxymethyllysine Advanced Glycation End Products (AGE) in Serum of Diabetic Patients

1999 ◽  
Vol 5 (6) ◽  
pp. 393-405 ◽  
Author(s):  
Masayoshi Takeuchi ◽  
Zenji Makita ◽  
Katsuyuki Yanagisawa ◽  
Yukihiko Kameda ◽  
Takao Koike
Keyword(s):  
Advanced Glycation End Products ◽  
Diabetic Patients ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products
Sign in / Sign up

Export Citation Format

Share Document